BibTex RIS Cite

KIRIM-KONGO KANAMALI ATEŞİ

Year 2009, Volume: 10 Issue: 2, 45 - 52, 01.08.2009

Abstract

Kırım Kongo Kanamalı Ateşi (KKKA) KKKA virüsü (KKKAV) tarafından oluşturulan bazen ölümcül olabilenviral bir hastalıktır. KKKA virüsü (KKKAV)BunyaviridaeailesininNairoviruscinsine ait olup kenelertarafından insanlara bulaştırılır. KKKA ilk kez 1944'de Kırım'da ortaya çıkmıştır. Günümüzde hastalık sıklıklaAsya, Afrika doğu Avrupa ve orta doğuda epidemiler yapmaktadır. Ülkemizde ilk olgular 2002 yılında raporedilmiştir. Hasta sayısı, 2007 yılına kadar 1820'ye yaşamını yitirenlerin sayısı ise 92'ye ulaşmıştır. Hastalıkülkemizde özellikle kuzeydoğu Anadolu'da görülmekle birlikte son yıllarda batı illerinden de olgubildirimlerinde artışlar söz konusudur. Aydın ili hastalık açısından nonendemik kabul edilmesine karşın ilkolgular 2006 yılında saptanmış ve görülen olgu sayısı 29'a ulaşmıştır. Bu yazıda KKKA ile ilgili genel bilgilerinverilmesi ile birlikte ilimizde görülen olguların klinik analizlerinin yapılması amaçlanmıştır

References

  • 1. El al dı N. Kırım-Kongo hemorajik ate şi epidemiyolojisi. Klimik Derg 2004;17:151-6.
  • 2. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006;6:203-14.
  • 3. T.C. Sağlık Bakanlığı, Temel Sağlık Hizmetleri Genel Müdürlüğü. Kırım-Kongo kanamalı ateşi. http://www.kirim-kongo.saglik.gov.tr/G3.doc/ 08.07.2008
  • 4. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol 2005;54:385-9.
  • 5. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with CrimeanCongo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004;39:284-7.
  • 6. Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R, Akdogan E, Eren N, Koksal I, Ovali E, Erickson BR, Vincent MJ, Nichol ST, Comer JA, Rollin PE, Ksiazek TG. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004;10:1379-84.
  • 7. European Centre for Disease Prevention and Control. Crimean-Congo hemorrhagic fever - information for travellers to north-eastern Turkey. 20 July 2006.
  • 8. Ergonul O, Zeller H, Kilic S, Kutlu S, Kutlu M, Cavusoglu S, Esen B, Dokuzoguz B. Zoonotic infections among veterinarians in Turkey: CrimeanCongo hemorrhagic fever and beyond. Int J Infect Dis 2006;10:465-9.
  • 9. The Turkish Ministry of Health. The reports of Communicable Diseases Department.Ankara, 2006.
  • 10. Midilli K. Kırım Kongo kanamalı ateşi virüsünün biyolojik ve moleküler epidemiyolojisi. 3. Ulusal Viroloji Kongre Kitabı, Bursa, 2007: 195-8.
  • 11. Tonbak S, Aktas M, Altay K, Azkur AK, Kalkan A, Bolat Y, Dumanli N, Ozdarendeli A. Crimean-Congo hemorrhagic fever virus: genetic analysis and tick survey in Turkey. J Clin Microbiol 2006;44:4120-4.
  • 12. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004;64:145-60.
  • 13. Morikawa S, Saijo M, Kurane I. Recent progress in molecular biology of Crimean-Congo hemorrhagic fever. Comp Immunol Microbiol Infect Dis 2007;30:375-89.
  • 14. Vatansever Z. Kırım Kongo Kanamalı Ateşi Epidemiyolojisinde Çevresel, Vektörel, İklimsel Değişikliklerin Rolü. 3. Ulusal Viroloji Kongre Kitabı, Bursa, 2007: 203-6.
  • 15. Gargılı A, Midilli K. Türkiye kenelerinde KırımKongo kanamalı humması ve tick borne ensefalit etkenlerinin nested RT-PCR yöntemiyle aranması, etkenlerin moleküler tüplendirilmesi ve infeksiyon odaklarının belirlenmesi. TÜBİTAK Proje Raporu, 2007.
  • 16. GargılıA. Kırım Kongo KanamalıAteşi'nin Vektörleri, Vektör Biyolojisi. 3. Ulusal Viroloji Kongre Kitabı, Bursa, 2007: 200-2.,
  • 17. Çevik M. Kırım-Kongo Kanamalı ateşi: Klinik özellikleri. Klimik Derg 2004;17:59-61.
  • 18. Papa A, Bino S, Llagami A, Brahimaj B, Papadimitriou E, Pavlidou V, Velo E, Cahani G, Hajdini M, Pilaca A, Harxhi A, Antoniadis A. Crimean-Congo hemorrhagic fever in Albania, 2001. Eur J Clin Microbiol Infect Dis 2002;21:603-6.
  • 19. Schwarz TF, Nsanze H, Ameen AM. Clinical features of Crimean-Congo haemorrhagic fever in the United Arab Emirates. Infection 1997;25:364-7.
  • 20. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin Microbiol Infect 2006;12:551-4.
  • 21. Ozkurt Z, Kiki I, Erol S, Erdem F, Yilmaz N, Parlak M, Gundogdu M & Tasyaran MA. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006;52:207-15.
  • 22. Centre for Disease Prevention and Control. Viral hemorrhagic fever initial management of suspected and confirmed cases. MMWR Morb Mortal WKLY Rep 1983;32:275 - 85.
  • 23. van Eeden PJ, Joubert JR, van de Wal BW, King JB, de Kock A, Groenewald JH. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part I. Clinical features. S Afr Med J 1985;68:711-7.
  • 24. Tasyaran MA, Özkurt Z. Kırım-Kongo hemorajik ateşi: Tedavi ve korunma. Klimik Derg 2004;17:157-60.
  • 25. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, MeyerhoffA, O'Toole T,Ascher MS, Bartlett J, Breman JG, Eitzen EM, Jr., Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287:2391-405.
  • 26. Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection.Antiviral Res 1993;22:309-25.
  • 27. T.C. Sağlık Bakanlığı, Temel Sağlık Hizmetleri Genel Müdürlüğü. Kırım Kongo kanamalı ateşi. 1. Baskı: Ankara: T.C. Sağlık Bakanlığı, 2005.
  • 28. World Health Organization. Crimean-Congo haemorrhagic fever. http://www.who.int/mediacentre/factsheets/fs208/en/ 10 June 2008
  • 29. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congohaemorrhagic fever treated with oral ribavirin. Lancet 1995;346:472-5.
  • 30. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of crimeancongo hemorrhagic fever in Iran. Clin Infect Dis 2003;36:1613-8.
  • 31. Smego RA Jr, Sarwari AR, Siddiqui AR. CrimeanCongo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin Infect Dis 2004;38:1731-15.
  • 32. Centre for Disease Prevention and Control. Update: management of patients with suspected viral haemorrhagic fever. MMWR Morb Mortal WKLY Rep 1995 44 475-479.

Crimean-Congo Hemorrhagic Fever

Year 2009, Volume: 10 Issue: 2, 45 - 52, 01.08.2009

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a fatal viral infection by Crimean-Congo hemorrhagic fever virus (CCHFV). Crimean-Congo hemorrhagic fever virus which is member of the Bunyaviridae family, Nairovirus genus is transmitted to humans through infected ticks. Crimean-Congo hemorrhagic fever was first recognized in the Crimean peninsula in 1944. The disease now occurs frequently throughout Asia, Africa, Eastern Europe and the Middle East. First cases have been reported in Turkey in 2002. 1820 cases and 92 deaths were reported until 2007. In our country, cases have especially been seen northern-east Anatolia. There has been a substantial increase in cases reports from the west part ofTurkey recently. HoweverAydın is nonendemic, first cases detected in 2006 and the number of cases have been reached 29.We aimed to inform on Crimean-Congo hemorrhagic fever and to analyze the clinical properties of detected cases.

References

  • 1. El al dı N. Kırım-Kongo hemorajik ate şi epidemiyolojisi. Klimik Derg 2004;17:151-6.
  • 2. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006;6:203-14.
  • 3. T.C. Sağlık Bakanlığı, Temel Sağlık Hizmetleri Genel Müdürlüğü. Kırım-Kongo kanamalı ateşi. http://www.kirim-kongo.saglik.gov.tr/G3.doc/ 08.07.2008
  • 4. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol 2005;54:385-9.
  • 5. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with CrimeanCongo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004;39:284-7.
  • 6. Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R, Akdogan E, Eren N, Koksal I, Ovali E, Erickson BR, Vincent MJ, Nichol ST, Comer JA, Rollin PE, Ksiazek TG. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004;10:1379-84.
  • 7. European Centre for Disease Prevention and Control. Crimean-Congo hemorrhagic fever - information for travellers to north-eastern Turkey. 20 July 2006.
  • 8. Ergonul O, Zeller H, Kilic S, Kutlu S, Kutlu M, Cavusoglu S, Esen B, Dokuzoguz B. Zoonotic infections among veterinarians in Turkey: CrimeanCongo hemorrhagic fever and beyond. Int J Infect Dis 2006;10:465-9.
  • 9. The Turkish Ministry of Health. The reports of Communicable Diseases Department.Ankara, 2006.
  • 10. Midilli K. Kırım Kongo kanamalı ateşi virüsünün biyolojik ve moleküler epidemiyolojisi. 3. Ulusal Viroloji Kongre Kitabı, Bursa, 2007: 195-8.
  • 11. Tonbak S, Aktas M, Altay K, Azkur AK, Kalkan A, Bolat Y, Dumanli N, Ozdarendeli A. Crimean-Congo hemorrhagic fever virus: genetic analysis and tick survey in Turkey. J Clin Microbiol 2006;44:4120-4.
  • 12. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004;64:145-60.
  • 13. Morikawa S, Saijo M, Kurane I. Recent progress in molecular biology of Crimean-Congo hemorrhagic fever. Comp Immunol Microbiol Infect Dis 2007;30:375-89.
  • 14. Vatansever Z. Kırım Kongo Kanamalı Ateşi Epidemiyolojisinde Çevresel, Vektörel, İklimsel Değişikliklerin Rolü. 3. Ulusal Viroloji Kongre Kitabı, Bursa, 2007: 203-6.
  • 15. Gargılı A, Midilli K. Türkiye kenelerinde KırımKongo kanamalı humması ve tick borne ensefalit etkenlerinin nested RT-PCR yöntemiyle aranması, etkenlerin moleküler tüplendirilmesi ve infeksiyon odaklarının belirlenmesi. TÜBİTAK Proje Raporu, 2007.
  • 16. GargılıA. Kırım Kongo KanamalıAteşi'nin Vektörleri, Vektör Biyolojisi. 3. Ulusal Viroloji Kongre Kitabı, Bursa, 2007: 200-2.,
  • 17. Çevik M. Kırım-Kongo Kanamalı ateşi: Klinik özellikleri. Klimik Derg 2004;17:59-61.
  • 18. Papa A, Bino S, Llagami A, Brahimaj B, Papadimitriou E, Pavlidou V, Velo E, Cahani G, Hajdini M, Pilaca A, Harxhi A, Antoniadis A. Crimean-Congo hemorrhagic fever in Albania, 2001. Eur J Clin Microbiol Infect Dis 2002;21:603-6.
  • 19. Schwarz TF, Nsanze H, Ameen AM. Clinical features of Crimean-Congo haemorrhagic fever in the United Arab Emirates. Infection 1997;25:364-7.
  • 20. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin Microbiol Infect 2006;12:551-4.
  • 21. Ozkurt Z, Kiki I, Erol S, Erdem F, Yilmaz N, Parlak M, Gundogdu M & Tasyaran MA. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006;52:207-15.
  • 22. Centre for Disease Prevention and Control. Viral hemorrhagic fever initial management of suspected and confirmed cases. MMWR Morb Mortal WKLY Rep 1983;32:275 - 85.
  • 23. van Eeden PJ, Joubert JR, van de Wal BW, King JB, de Kock A, Groenewald JH. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part I. Clinical features. S Afr Med J 1985;68:711-7.
  • 24. Tasyaran MA, Özkurt Z. Kırım-Kongo hemorajik ateşi: Tedavi ve korunma. Klimik Derg 2004;17:157-60.
  • 25. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, MeyerhoffA, O'Toole T,Ascher MS, Bartlett J, Breman JG, Eitzen EM, Jr., Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287:2391-405.
  • 26. Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection.Antiviral Res 1993;22:309-25.
  • 27. T.C. Sağlık Bakanlığı, Temel Sağlık Hizmetleri Genel Müdürlüğü. Kırım Kongo kanamalı ateşi. 1. Baskı: Ankara: T.C. Sağlık Bakanlığı, 2005.
  • 28. World Health Organization. Crimean-Congo haemorrhagic fever. http://www.who.int/mediacentre/factsheets/fs208/en/ 10 June 2008
  • 29. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congohaemorrhagic fever treated with oral ribavirin. Lancet 1995;346:472-5.
  • 30. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of crimeancongo hemorrhagic fever in Iran. Clin Infect Dis 2003;36:1613-8.
  • 31. Smego RA Jr, Sarwari AR, Siddiqui AR. CrimeanCongo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin Infect Dis 2004;38:1731-15.
  • 32. Centre for Disease Prevention and Control. Update: management of patients with suspected viral haemorrhagic fever. MMWR Morb Mortal WKLY Rep 1995 44 475-479.
There are 32 citations in total.

Details

Other ID JA97CA94PF
Journal Section Collection
Authors

Sevin Kırdar This is me

M. Bülent Ertugrul This is me

Publication Date August 1, 2009
Published in Issue Year 2009 Volume: 10 Issue: 2

Cite

EndNote Kırdar S, Ertugrul MB (August 1, 2009) Crimean-Congo Hemorrhagic Fever. Meandros Medical And Dental Journal 10 2 45–52.